Aarti Drugs Limited delivered a strong start to FY27, reporting consolidated revenue of ₹703.6 crore in Q1FY27, up 19% year-on-year from ₹590.8 crore in Q1FY26. The growth was primarily driven by higher API realizations amid geopolitical tensions in West Asia and steady volume expansion across key therapeutic categories. EBITDA surged 30% to ₹96.9 crore, with margins expanding by 120 basis points to 13.8%. Profit before tax (PBT) grew 35% to ₹69.2 crore, though net profit (PAT) stood at ₹50.1 crore, down from ₹54.0 crore in the prior year quarter which included a ₹15 crore principal tax refund.

The company’s stand-alone revenue reached ₹627.6 crore, marking a 20% YoY growth. Domestic revenue grew 25% while exports expanded 12%, contributing 32% of the stand-alone total. The formulations segment saw an 8% YoY revenue increase to ₹81.6 crore, with exports accounting for 74% of this segment’s sales. Management highlighted that operational stability was maintained despite global supply chain disruptions, with no production delays or material shortages affecting customer commitments.

Key Financial Metrics

Operational Updates and Capacity Expansion

The Sayakha facility, a key strategic investment for backward integration, operated at nearly 65% utilization during the quarter. This facility is critical for producing intermediates for the antidiabetic segment, particularly metformin. Management noted that captive consumption from Sayakha is expected to rise to 80-90% in subsequent quarters, potentially adding 1% to gross contribution. Additionally, the brownfield expansion at the Baddi formulation facility is progressing as planned, aiming to nearly double oral solid dosage manufacturing capacity upon completion.

What the Numbers Show

While net profit declined nominally, the operational performance indicates robust underlying strength. The 30% EBITDA growth outpaced the 19% revenue growth, signaling effective cost management and pricing power. The divergence between PAT and EBITDA trends is largely attributable to the one-time tax refund in Q1FY26 rather than operational weakness. Furthermore, the significant margin expansion despite elevated raw material and freight costs demonstrates the resilience of Aarti Drugs’ integrated manufacturing model and its ability to pass on price increases to customers.

Market Dynamics and Outlook

Geopolitical conflicts have led to volatile raw material prices and elevated freight costs, but also created a favorable pricing environment for APIs. Metformin prices, for instance, remained 15-20% higher than pre-conflict levels. Management expects volume growth to improve in coming quarters as inventory levels normalize, targeting 10-15% volume growth over the next two years. The company is also focusing on expanding its presence in regulated markets, with USFDA approvals pending for new metformin capacity and ongoing business development for existing USFDA-approved facilities.

Aarti Drugs will host an investor meeting on August 10, 2026, providing analysts and institutional investors with an opportunity to engage with company officials. The event, organized by Nirmal Bang, is scheduled to take place at Trident BKC in Mumbai from 11:00 AM to 1:00 PM. This interaction aims to facilitate dialogue based on publicly available information, ensuring transparency for market participants without disclosing any unpublished price-sensitive information (UPSI).

The company issued the intimation pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) on August 4, 2026. Rushikesh Vivek Deole, Company Secretary and Compliance Officer of Aarti Drugs Limited, signed the disclosure, confirming the schedule and compliance with regulatory norms.

Meeting Details

The specific details of the scheduled interaction are outlined below:

Management emphasized that the discussions during the meet will be strictly confined to publicly available data. The company noted that changes to the schedule may occur due to exigencies on the part of the host or the company, though no such alterations have been reported as of the filing date.

Regulatory Compliance

The disclosure aligns with the mandatory requirements under Regulation 30(6) of the SEBI LODR Regulations, 2015, which mandates listed entities to inform stock exchanges about meetings with analysts or institutional investors. By proactively sharing the schedule, Aarti Drugs ensures that all market participants have equal access to the opportunity to interact with management, thereby upholding fair disclosure practices.

No unpublished price-sensitive information is intended to be discussed during these interactions. Investors are advised that any material developments arising from such meetings would be separately disclosed through official channels if they constitute price-sensitive information.